B1NT34:BVMF
Biontech Se Bdr
R$31.52
arrow_downward
-3.64%(-1.19) 1D
Sep 8, 4:56:00 PM GMT-3 · BRL
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for B1NT34...
Open
R$32.43
High
R$32.82
Low
R$31.52
Mkt. cap
24.80B
Avg. vol.
2.12K
Volume
289.00
52-wk high
R$41.00
52-wk low
R$25.78
Shares outstanding
252.88M
No. of employees
8K
Open
R$32.43
High
R$32.82
Low
R$31.52
Mkt. cap
24.80B
Avg. vol.
2.12K
Volume
289.00
52-wk high
R$41.00
52-wk low
R$25.78
Shares outstanding
252.88M
No. of employees
8K
News stories
From web sources and news partners
Kalkine Media
·
10 hours ago
BioNTech CEO Ugur Sahin Executes Sale of 76,500 Shares Under Rule 10b5-1 Plan
Simply Wall Street
·
11 hours ago
How Trial Termination At BioNTech (BNTX) Has Changed Its Investment Story
Investing.com
·
19 hours ago
BMO lowers Amgen, BioNTech to Market Perform as risk-reward shifts
Yahoo Finance
·
20 hours ago
BioNTech Shares Fall After BMO Downgrade and Price Target Cut
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About Biontech Se Bdr